Trial Profile

A First-in-Human Phase I Single-Agent Open-Label Dose-Escalation Study of Every Three-Week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dordaviprone (Primary)
Indications Endometrial cancer; Glioblastoma; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

04 Jun 2019 Results presented in an Oncoceutics media release.
04 Jun 2019 According to an Oncoceutics media release, results from the study were published in the Journal for ImmunoTherapy of Cancer.
05 Jun 2018 Results of pooled data from two phase 1 trial (NCT02250781 and NCT02324621), were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com